Published in Vaccine Weekly, October 22nd, 2003
"The investigated tumor markers in renal cell carcinoma (RCC) may show additional prognostic value over classical prognostic factors such as stage and grade. These markers can be used for better patient selection, a more accurate individualization of treatment, and improved follow-up," investigators in the Netherlands report.
"Tumor antigens that are specific to RCC and that induce a specific immune response can be used for vaccine treatment modalities," said Peter Mulders and colleagues at the University of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2003-10-22)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.